Introduction: New methods for coagulation tests require careful assessment before
| INTRODUC TI ON
Coagulopathies occur in patients across all healthcare settings, often resulting in clinically significant bleeding or thrombosis, depending on the nature of the defect. [1] [2] [3] [4] [5] [6] A number of possible aetiologies exist, including trauma, disease (eg, liver disease, sepsis, cancer), surgery, pharmacological treatment (eg, unfractionated heparin [UFH], vitamin K antagonists, direct factor Xa-and direct thrombin inhibitors) and genetic or acquired deficiencies in coagulation factors. 3, [7] [8] [9] [10] [11] The ability to accurately, reliably and quickly measure indicators of haemostatic function, and to subsequently implement corrective measures, is thus important for patient health.
Coagulation tests are used widely for the screening, diagnosis and assessment of coagulopathies, and for the monitoring of anticoagulant and antithrombotic therapies. 5, [8] [9] [10] [12] [13] [14] [15] [16] [17] [18] [19] In particular, assessments of prothrombin time (PT) and activated partial thromboplastin time (aPTT), relating to the activity of the extrinsic/common and intrinsic/common pathways of coagulation, respectively, are widely used to detect hypocoagulation. 4, 5, 8, [15] [16] [17] [20] [21] [22] [23] [24] [25] The current generation of automated, high-throughput coagulation analysers provides scope for improved turnaround times in core laboratories, as well as for potential expansion of the range of tests offered. Five new commercially available assays (PT Rec, PT Owren, aPTT, aPTT Lupus and aPTT Screen) have recently become available for use on cobas t coagulation analysers, and may offer potential advantages over existing assays/platforms in terms of handling, precision and throughput. Prior to their adoption, it is important that new assays are evaluated for precision, compared with existing methods and that relevant reference ranges are established, thus ensuring that the assays are suitable for routine use in core laboratories and able to reliably inform clinical decisions. 26, 27 This multicentre study evaluated the performance of the five new coagulation assays on the cobas t analysers. For each assay, the analytical performance was evaluated and a method comparison with existing, commercially available assays/platforms was performed; reference ranges for each assay were also determined using samples from apparently healthy volunteers.
| MATERIAL S AND ME THODS

| Study design
The study was performed between June 2016 and March 2017 in core laboratories at four centres in Europe (University of Freiburg, Germany; Royal Hallamshire Hospital, Sheffield, UK; University of Debrecen, Hungary; AKH Wien, Austria).
Five assays (PT Rec, PT Owren, aPTT, aPTT Lupus and aPTT Screen; Roche Diagnostics GmbH, Mannheim, Germany) were each evaluated for their analytical performance, and compared with existing methodologies/technologies (see below) in independent method comparison experiments; lot-to-lot variability, the equivalency of each assay on two cobas t platforms and reference ranges in apparently healthy volunteers were also assessed. 
| Assay principles
The PT Rec assay contains thromboplastin (recombinant human thromboplastin reagent containing a heparin-neutralizing substance) and calcium, which initiate the activation of the extrinsic coagulation cascade when added to citrated human plasma. 23 The PT Owren assay reagent contains rabbit brain thromboplastin plus bovine plasma (containing factor V and fibrinogen and lacking factors II, VII and X) and a heparin neutralizer. 28 
| Analytical performance
| Method comparison
Method 
| Equivalency of the cobas t analysers
Equivalency of the cobas t 511 and cobas t 711 platforms was evaluated by method comparison, using each of the five assays (PT Rec,
PT Owren, aPTT, aPTT Lupus and aPTT Screen). A minimum of 120
anonymized human plasma samples were tested on each platform at each of the two sites (Freiburg and Sheffield; one reagent lot per site).
| Lot-to-lot comparison
Lot-to-lot comparability was assessed for each assay on the cobas t 711 analyser. Each assay was tested using three reagent lots (two lots per site) and a minimum of 120 anonymized human plasma samples per comparison.
| Reference range studies
Reference ranges for each assay were determined using anonymized residual samples from apparently healthy adult donors (0.109M/3.2% citrate) sourced from a blood bank; samples were measured fresh at the sampling site in Freiburg, Germany. Inclusion criteria were apparently healthy adults (aged 18-50 years and originating from Europe or the US) and able to provide written informed consent; exclusion criteria were self-declared pregnancy or breast-feeding, and use of anticoagulation medication including but not limited to acetyl sali- 
| Sensitivity analysis of aPTT, aPTT Lupus and aPTT Screen assays to heparin and lupus anticoagulant
Sensitivity of the three new aPTT assays towards UFH and LA was analysed. The presence of warfarin (UFH analyses) or any anticoagulant (LA analyses) therapy was excluded by testing with PT (Thromborel S reagent), TT (BC Thrombin) and anti-Xa (Hyphen Biophen UFH Liquid Reagent Technology). Therapeutic ranges for the three aPTT assays were also determined according to CLSI H47-A2 guidelines, using linear regression.
Platelet-poor samples (n = 117) were sourced from patients receiving UFH, and each sample was measured with three Roche aPTT reagents on a cobas t 711 analyser. Results were compared against measurements from three Siemens aPTT reagents (Actin FS, Actin FSL and Pathrombin SL) on a BCS XP system.
Lupus anticoagulant-positive plasma samples (n = 96) were sourced commercially (Clinisys) and the LA ratio determined for each sample on a BCS XP system with LA1 and LA2 reagents (Siemens).
The sensitivity of the three aPTT assays on a cobas t 711 analyser was assessed by comparison with the LA ratio.
| Data analysis
Assay output was captured directly using WinCAEv, a CFR 21 Part 11 compliant electronic data capture software developed and validated for Roche-sponsored studies. 32 The coefficient of variation (CV) was calculated for within-run precision and reproducibility and compared against prespecified acceptance ranges (within-run preci- Screen assays, as acceptance criteria were defined in these units.
Bias was examined using Bland-Altman analysis.
Reference ranges (seconds) were calculated based on the 2.5th and 97.5th percentile values of the series of measurements for each assay with 90% confidence intervals (CI); median values were also estimated.
| RE SULTS
| Analytical performance
For each assay, the CVs for within-run precision and total reproducibility are presented in Table 1 ; all values were within the prespecified acceptance criteria. Across all five assays, CVs for within-run precision of the human sample pools, across all four sites, ranged from 0.2% to 1.3% on the cobas t 711 analyser, and from 0.1% to 0.8% on the cobas t 511 analyser; CVs for total reproducibility across all four sites ranged from 0.8% to 3.4% on the cobas t 711 analyser, and from 0.3% to 6.3% on the cobas t 511 analyser.
| Method comparison
Method comparison experiments demonstrated good agree- 
| Equivalency of cobas t 711 and cobas t 511 analysers
For each of the five assays evaluated, the cobas t 711 and cobas t 511 platforms demonstrated equivalence, according to prespecified acceptance criteria, based on Passing-Bablok regression analyses (Table 3) . Across all assays (n = 5) and sites (n = 2 sites per assay, except PT Owren where n = 1 site), Pearson's correlation coefficient was ≥0.995. Bland-Altman plots are presented ( Figures S6-S10 ) and demonstrate constant bias for the five assays, with consistent results for the two sites.
| Lot-to-lot comparison
A high level of consistency between lots was observed for all five assays (cobas t 711 analyser); the specified equivalence criteria based on Passing-Bablok analyses were met (Table 4) 
| Reference range
Based on fresh samples in Sarstedt tubes, reference ranges (2.5th to 97.5th percentiles [90% CI]; n = 200 fresh samples per assay) in seconds TA B L E 1 Within-run precision and total reproducibility (across all four sites) of the five coagulation assays on the cobas t 711 and cobas t 511 analysers, based on human plasma pools (range for the five human plasma pools is presented) 
| Sensitivity of the aPTT, aPTT Lupus and aPTT Screen assays towards heparin and lupus anticoagulant
The therapeutic range for the aPTT assays was shorter than for the 
| D ISCUSS I ON
The five assays demonstrated excellent analytical performance on both the cobas t 711 and cobas t 511 analysers. Overall, CVs for within-run precision were ≤1.3% and those for total reproducibility were ≤6.3%; lot-to-lot comparisons with each assay showed a high level of consistency across all sites. Furthermore, each of the five assays performed on the cobas t 711 analyser showed good agreement with the commercially available assays/platforms used as comparator methods, which have previously demonstrated favourable performance for the measurement of their respective analytes. [34] [35] [36] The reference range in apparently healthy volunteers measured with the aPTT assay was consistent with those previously reported for other assays/platforms, 20, 34, 35 and the reference ranges for the aPTT Lupus and aPTT Screen assays were in line with those of the aPTT assay. The reference range for the PT Rec assay (8.4-10.6 seconds) was slightly lower than that previously reported for similar assays. 34, 37 Reference ranges for each assay were consistent whether fresh or frozen samples were used, and with two different types of sample tube.
Together, these assays provide core laboratories with a method for monitoring anticoagulant therapy and for screening for specific coagulation abnormalities. For example, the PT Rec and PT Owren assays are intended to aid in the management of vitamin K antagonist therapy and PT Rec may also be used as a diagnostic tool for liver function testing. 17, 23, 28, 38 Compared with PT Rec, the PT Owren assay is designed to be less sensitive to interference by lupus antibodies and is insensitive to variations in factor V and fibrinogen; the PT clotting time measured with both assays is not influenced by therapeutic plasma concentrations of UFH or lowmolecular-weight heparin (data not shown). 28 The aPTT assays provide a means of screening for abnormalities in intrinsic coagulation pathway factors VIII, IX, XI, XII and common pathway factors II, V, Strengths of the study include the multicentre design (including four core laboratories in different European countries) and adherence to CLSI guidelines. Furthermore, method comparisons were performed against relevant commercially available assays/ platforms and reference ranges were established for each assay using samples from 200 apparently healthy volunteers. Although not a limitation of the study design, which aimed to assess the analytical performance of the assays and their interchangeability with existing commercially available methods, the authors note that this study did not aim to assess the clinical performance of the assays on the cobas t analysers in terms of their ability to detect abnormalities in coagulation factors, or assess therapeutic drug levels; nevertheless, checks of factor-deficient samples included in the study showed that the assays were able to detect the deficiencies adequately (data not shown).
In summary, based on the excellent analytical performance and good agreement with relevant comparator methods, the five coagulation assays on the novel cobas t 711 and cobas t 511 analysers are suitable for routine use in core laboratories.
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